Hematopoietic stem cells (HSCs) are uniquely capable of selfrenewal and provision of all of the mature elements of the blood and immune system throughout the lifetime of an individual. HSC self-renewal is regulated by both intrinsic mechanisms and extrinsic signals mediated via specialized microenvironments or 'niches' wherein HSCs reside. HSCs have been shown to reside in close association with bone marrow (BM) osteoblasts in the endosteal niche and also in proximity to BM sinusoidal vessels. An unresolved question surrounds whether the endosteal and vascular niches provide synchronous or redundant regulation of HSC fate or whether these niches provide wholly unique regulatory functions. Furthermore, while some aspects of the mechanisms through which osteoblasts regulate HSC fate have been defined, the mechanisms through which the vascular niche regulates HSC fate remain obscure. Here, we summarize the anatomic and functional basis supporting the concept of an HSC vascular niche as well as the precise function of endothelial cells, perivascular cells and stromal cells within the niche in regulating HSC fate. Lastly, we will highlight the role of the vascular niche in regulating leukemic stem cell fate in vivo. Leukemia (2012) 
Concept of the hematopoietic stem cell (HSC) niche
The concept of an instructive role for the bone marrow (BM) microenvironment in regulating hematopoietic cell fate was introduced at least 50 years ago and has been validated over the past decade. [1] [2] [3] [4] [5] [6] [7] [8] [9] It has long been postulated that HSCs reside in specialized niches within the adult BM. [8] [9] [10] [11] [12] [13] [14] In addition to HSCs and their progeny, the BM comprises a rich network of osteoblasts, mesenchymal stem cells (MSCs), neuronal cells, adipocytes, sinusoidal vessels and perivascular reticular cells ( Figure 1 ). Recently, genetic knockout studies have begun to demonstrate the functional role of specific cells within the BM microenvironment in regulating hematopoiesis. [3] [4] [5] 7, [15] [16] [17] [18] [19] [20] Interestingly, certain niches within the BM may uniquely regulate HSC homeostasis in vivo while other niches may be more relevant to HSC regeneration following injury. However, it remains unknown whether there is meaningful 'cross-talk' between distinct microenvironmental cells in regulating HSC fate in vivo. Interestingly, as early as 1961, Fliedner et al. 9 postulated that the recovery of hematopoiesis in rats following 1000 cGy total body irradiation (TBI) required the recovery of an intact vasculature. Similarly, McClugage et al.
14 used a window chamber to visualize dynamic changes in tibial BM cellularity and architecture in live rabbits. Interestingly, both studies suggested a strong association between vasculogenesis in the BM and the hematopoietic response to stress or injury. 9, 14 Role of the BM osteoblast
With advances in mouse genetics and microscopy, the function of the BM osteoblast in regulating hematopoiesis and HSC homeostasis has been demonstrated. 4, 5, 14, [21] [22] [23] [24] Human osteoblasts were shown by Taichman and Emerson 21 to regulate the myeloid differentiation of human CD34 þ progenitor cells in culture via the production of granulocyte colony stimulating factor. BM osteoblasts were also shown to promote B-cell differentiation of murine hematopoietic progenitors in culture and depletion of BM osteoblasts in Col2.3D-TK mice resulted in a loss of pre-B-cell content in vivo. 22 The function of BM osteoblasts in regulating HSC fate was first suggested by Taichman et al., 23 who showed that in vitro culture of human BM CD34 þ cells with human osteoblasts supported a 3-4-fold expansion of long-term culture-initiating cells in vitro. More recently, the function of the BM osteoblast in regulating HSC pool size was demonstrated by Calvi et al., 4 who showed that activation of the parathyroid hormone/parathyroid hormone receptor in vivo increased BM osteoblast and trabecular bone content, yielding a significant increase in BM HSC numbers. Similarly, Zhang et al. 24 showed that conditional inactivation of the bone morphogenetic protein receptor 1A in mice caused an increase in BM osteoblast numbers which, in turn, increased BM HSC content. Taken together, these studies revealed that BM osteoblasts positively regulate BM HSC pool size in vivo and suggested that BM osteoblasts regulate HSC content via Notch ligand and N-cadherin interactions. 4, 24 Subsequently, Arai et al. 15 showed that BM osteoblasts regulate HSC quiescence via angiopoietin-Tie2 signaling in the BM. The therapeutic relevance of the BM osteoblastic niche for amplification of the HSC pool has also been demonstrated by Adams et al., 5 who showed that administration of parathyroid hormone to mice for several weeks resulted in augmentation of the BM osteoblast pool and an associated significant increase in BM HSCs in vivo. The combination of parathyroid hormone followed by granulocyte colony stimulating factor administration significantly augmented peripheral blood HSC mobilization and this approach has subsequently been tested in phase I clinical trials. 5, 25 Recent studies have further refined our understanding of the BM osteoblastic niche and the mechanisms through which it regulates the HSC pool. Using an MxCre model, Kiel et al. 26 demonstrated that N-cadherin expression was not necessary for BM HSC maintenance in the BM osteoblastic niche and Stier et al. 27 demonstrated that BM osteoblasts inducibly produce osteopontin, an extracellular matrix protein, which negatively
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regulates HSC pool size in vivo. 27 In vivo microscopic imaging of the calvarial BM in living mice has also revealed that transplanted Flt3
À c-kit
HSCs home to the endosteum following irradiation conditioning. 28 Interestingly, these same studies revealed that BM HSCs home predominantly to sinusoidal vasculature in mice that were not conditioned with TBI. 28 An important caveat to these studies is that the endosteum is highly vascularized in the calvarium, so discrimination of HSC homing to endosteum versus vasculature was somewhat limited by the anatomic site. Nonetheless, these studies clearly demonstrated that transplanted HSCs home to areas adjacent to endosteal bone and suggested a possible interplay between the BM endosteal niche and the vascular niche for HSCs in vivo.
Role of BM stromal cells
In addition to the established role of BM osteoblasts in regulating HSC fate in vivo, other cell types also regulate HSC content and function. Specifically, perivascular CXCL12-abundant reticular cells were shown to be necessary for maintenance of BM HSC content in vivo. 
Origins in embryogenesis
During embryogenesis, definitive hematopoiesis originates in the developing aorto-gonado-mesonephros region. [29] [30] [31] [32] Shalaby et al. 29 showed that mice lacking Flk1, a tyrosine kinase expressed on endothelial progenitor cells, failed to develop both vascular endothelium and blood islands during embryogenesis. Choi et al. 30 subsequently demonstrated via gene tracing studies that vascular endothelial and hematopoietic cells arise in vitro from a common precursor cell, the hemangioblast. The onset of definitive hematopoiesis was shown by different investigators to occur at the site of the dorsal aorta at E10.5-11.5 within the aorto-gonado-mesonephros region. 31, 32 Several complementary studies using lineage tracing experiments in both mice and zebrafish have subsequently shown that HSCs arise from hemogenic endothelium within the ventral aspect of the dorsal aorta. [33] [34] [35] Runx1 is required for this process to occur in mice 36 and HSCs, which arise from hemogenic endothelium migrate to the fetal liver and to the BM and are capable of self-renewal and multilineage differentiation. 33 
Vascular regulation of adult hematopoiesis
Knospe et al. 13 provided some of the earliest evidence of vascular regulation of hematopoiesis when they reported that Figure 1 Schematic representation of the BM HSC niche(s). As shown, HSCs traverse and dynamically interact with multiple cell types within the BM microenvironment. Although schematically represented separately, the endosteal, mesenchymal and vascular niches are physically and functionally intertwined. Candidate niche mechanisms, which regulate HSC function are also shown, including Jagged-Notch, SDF1-CXCR4 and PTN signaling.
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Vascular niche for stem cells PL Doan and JP Chute hematopoietic regeneration in areas of curetted BM in adult mice corresponded with sites of BM sinusoidal vascular regeneration. The BM sinusoidal vasculature is radiosensitive but regenerates and reorganizes within 3-4 weeks following sublethal exposure. 18 However, at doses at or above 20 Gy, complete repair and regeneration of the BM sinusoidal vasculature does not occur. 37 Importantly, Rafii et al. 38, 39 showed that primary human BM endothelial cells (ECs) supported the proliferation and differentiation of human CD34 þ cells in culture and produced several hematopoietic cytokines. Interestingly, Davis et al. 40 described the expansion of human BM CD34 þ progenitor cells in culture with a porcine brain microvascular EC line, suggesting that ECs from non-hematopoietic tissues could also support HSC growth in vitro. Subsequent studies demonstrated that the porcine brain microvascular EC line was capable of supporting the maintenance of non-human primate (baboon) HSCs in vitro as well as human cord blood repopulating cells as measured in a xenograft transplant model. 41, 42 These studies provided foundation for several important questions to be addressed regarding the role of ECs in regulating hematopoiesis and, more specifically, HSC fate.
Do human ECs regulate human HSC fate?
On the basis of the studies of Davis et al. and Rafii et al., our laboratory sought to test whether human ECs regulated human HSC self-renewal. We screened several tissue sources of primary human ECs including dermal ECs, aortic ECs, umbilical vein ECs and human brain ECs (HUBECs) for the capacity to support human HSC growth in vitro. 43 Interestingly, we found that noncontact culture of human BM or cord blood HSCs with primary HUBECs induced a 10-fold expansion of human SCID-repopulating cells, suggesting that adult brain ECs produced soluble factors, which induce HSC self-renewal ( Figure 2) . 43, 44 Our group also demonstrated that co-culture of irradiated murine or human HSCs with adult human ECs facilitated the regeneration of HSCs with in vivo repopulating capacity following exposure to high dose irradiation. 45, 46 Furthermore, since the expansion of normal HSCs and regeneration of HSCs and progenitor cells in culture with human ECs was not dependent on cell-to-cell contact, we performed gene expression analysis for EC genes, which encoded for secreted proteins. A differential analysis of HSC-supportive HUBECs versus non-HSC-supportive human ECs revealed several candidate secreted proteins elaborated by HUBECs. 47 One protein, IGFBP-2, was shown by Zhang et al. 48 to support the expansion of human cord blood HSCs. We focused thereafter on functional screening of novel proteins expressed by HUBECs as candidate HSC growth factors.
Do ECs secrete soluble growth factors that mediate HSC self-renewal?
Several candidate proteins that were overexpressed by HUBECs were functionally screened to identify novel HSC growth factors. We focused on a heparin-binding growth factor, pleiotrophin (PTN), which was 25-fold overexpressed in HUBECs and highly concentrated in HUBEC conditioned media. 49 We found that treatment of murine BM CD34 À c-kit
HSCs with early acting cytokines (stem cell factor, thrombopoietin, Flt-3 ligand, thrombopoietin) and recombinant PTN caused a 10-fold amplification of long-term repopulating HSCs in culture compared with cytokines alone or input 34
À KSL cells (Figure 3) . 49 Importantly, systemic administration of PTN to mice following high dose TBI caused a 20-fold increase in BM HSC content in vivo compared with control animals, suggesting that PTN also promoted HSC regeneration following injury. Do BM ECs regulate hematopoietic cell fate in vivo?
In the past decade, several studies have yielded important insights into the function of BM ECs in regulating hematopoiesis in vivo. Heissig et al. 50 demonstrated the important function of matrix metalloproteinase-9 in regulating the proliferation and mobilization of hematopoietic progenitor cells in vivo via elaboration of soluble c-kit ligand. The investigators suggested a model in which soluble c-kit ligand facilitated the translocalization of HSCs to the BM vascular niche wherein proliferation and differentiation occurred before margination into the peripheral blood. 50 Subsequently, Avecilla et al. 51 showed that BM vascular regeneration in vivo following 5 fluorouracil chemotherapy was coincident with the re-establishment of thrombopoiesis in mice. These investigators demonstrated further that inhibition of BM vascular recovery via administration of anti-VE cadherin antibody caused a significant delay in platelet recovery in vivo, suggesting that recovery of thrombopoiesis was dependent on re-establishment of the BM vasculature. 51 In a complementary study, Kopp et al. 52 reported that inhibition of angiopoietin/Tie2 signaling in the BM vascular niche antagonized BM vascular regeneration following myelosuppression and this was associated with a significant delay in hematologic recovery. Collectively, these studies suggested an important function for BM ECs in regulating hematopoiesis and hematopoietic regeneration in vivo. However, the function of BM ECs in regulating HSC fate or regeneration was not specifically addressed in these studies.
An anatomic basis to support the concept of a vascular niche for HSCs was provided by Kiel et al., 6 who demonstrated that SLAM marker ( þ ) HSCs (CD150 þ CD244 À CD48 À lineage À BM cells) resided in close association with BM sinusoidal vessels and the endosteum. Lo Celso et al. 28 also showed via microscopic imaging of anesthetized mice that transplanted BM progenitor cells engrafted preferentially in BM vascular domains in animals that received no conditioning. Our laboratory subsequently showed that systemic infusion of syngenic ECs promoted the acceleration of both BM vascular regeneration, hematologic recovery and improved survival in mice following TBI (Figure 4) . 18 Allogeneic endothelial progenitor cell infusions were also shown to induce hematologic recovery and a quantitative increase in long-term repopulating HSC content compared with control mice following TBIinduced myelosuppression, suggesting that ECs positively regulated HSC reconstitution in vivo. 53 Interestingly, we found that transplanted ECs did not engraft directly in the BM vasculature, but rather engrafted temporarily in the lungs of recipient mice, suggesting that soluble factors were elaborated by infused ECs, which promoted vascular and HSC regeneration. 53 In keeping with these findings, Slayton et al. 54 demonstrated that, following BM transplantation, reconstitution of the BM vasculature derives predominantly from host ECs rather than donor-derived endothelial progenitor cells.
Recently, studies by Hooper et al. 16 suggested that BM sinusoidal ECs could be identified via co-expression of vascular endothelial growth factor receptor (VEGFR)2 and VEGFR3 and the absence of Sca-1. Importantly, these investigators showed that VEGFR2 -/-mice had delayed BM vascular regeneration and hematopoietic recovery in mice following TBI and systemic administration of anti-VEGFR2 antibody inhibited engraftment of HPCs in a transplantation model. 16 Our laboratory 53 and Butler et al. 19 also demonstrated that inhibition of BM vasculogenesis via systemic administration of an anti-VEcadherin antibody inhibits multilineage hematologic recovery following myelosuppression. Taken together, these studies confirm that BM EC-mediated signaling is necessary for normal hematopoietic regeneration following myelosuppression in vivo. It has been suggested also by studies from Himburg et al. 49 and Kobayashi et al. 55 that soluble factors produced by BM ECs may be responsible for HSC self-renewal and regeneration in vivo, but the mechanisms through which BM ECs mediate these processes remain unknown. A candidate factor that is secreted by BM ECs, PTN, was recently shown by Himburg et al. 49 to induce HSC regeneration in vivo when administered systemically to mice following high dose TBI and these effects may be mediated via binding and inhibition of the protein receptor tyrosine phosphatase-zeta (PTPRz) on BM HSCs. 49 An important research focus going forward will be to delineate the contactbased and soluble mechanisms through which BM ECs mediate hematopoietic regeneration in vivo. The leukemia stem cell niche(s) Induction therapy for acute myeloid leukemia (AML) has remained essentially unchanged for three decades. While response rates for AML approach 60-70%, the large majority of patients with acute leukemia will die from their disease. 56 It has been hypothesized that a principal reason for the incurability of acute leukemia is the presence of leukemia stem cells (LSCs), which are resistant to the cytotoxic effects of chemotherapy. 57, 58 Experimental evidence suggests that the incorporation of LSCs in facultative niches promotes the chemoresistance and regeneration of leukemia following induction and consolidation therapy. 59, 60 Advances in characterization of the niches wherein normal HSCs reside has provided the basis for examination of LSC niches and nichemediated mechanisms, which promote LSC engraftment and survival. Much of the current understanding of the biology of LSCs derives from studies of primary human AML cells transplanted into NOD-SCID or NOD-SCID IL2Rg null mice, 58, [61] [62] [63] [64] which are permissive for human cell engraftment. Using these xenograft models, it has been shown that AML cells have a phenotypic hierarchy, which parallels that of normal hematopoietic stem/progenitor cells. [65] [66] [67] [68] For example, it was shown that the CD34 þ CD38 À AML population could engraft efficiently in NOD-SCID mice, but the more differentiated CD34 þ CD38 þ and CD34 À AML cells were unable to engraft and yield colony-forming progenitors. 68 It was further shown that a primitive leukemic cell clone or LSC was responsible for the generation and maintenance of AML in these xenograft models, 67, 68 and the frequency of leukemia-initiating cells was determined to be 1 per 250 000 cells based on limiting dilution analysis. 68 Subsequent transplantation studies into NOD-SCID mice using human cord blood cells infected with the MLL-ENL and MLL-AF9 oncogenes demonstrated a frequency of leukemiainitiating cells at 1 in 2000 transplanted cells. 61, [69] [70] [71] As few as four MLL-AF9Finfected cells can sustain leukemia through serial transplantation in recipient mice, confirming the presence of an leukemia-initiating cell in this model of human acute leukemia. 70 Interestingly, other studies in mice have demonstrated that AML could be generated from either HSCs or committed progenitor cells, which attain properties of selfrenewing cells via oncogenic transformation. 65 The application of xenograft models has also led to initial characterization of some of the cellular mechanisms which regulate LSC engraftment and maintenance in the microenvironment. 58, 63 Ishikawa et al. 58 showed that human AML cells preferentially engrafted in the BM endosteal region in NOD-SCID/IL2Rg null mice following transplantation and remained adjacent to BM osteoblasts for up to 4 months post-transplantation. AML cells within the osteoblastic niche were shown to be primarily in G 0 and were protected from cytarabine-induced apoptosis. 58 Saito et al. 63 demonstrated that granulocyte colony stimulating factor administration induced cell cycle entry of human AML cells in NOD-SCID/IL2Rg null mice and the combined administration of granulocyte colony stimulating factor and cytarabine chemotherapy caused a significant reduction in human AML cells in vivo. These data suggest that the osteoblastic niche promotes the quiescence of human AML cells in vivo and pharmacologic strategies to induce cell cycling of AML cells followed by chemotherapy can increase leukemia cell cytotoxicity.
Interestingly, using intravital microscopy, Sipkins et al.
72
showed that transplanted Nalm-6 cells, a pre-B acute lymphoblastic leukemia (ALL) cell line, engrafted preferentially in association with microvascular domains in the BM. The transplanted Nalm-6 cells anchored to the BM vasculature and proliferated at this location through day 14 post-transplant. 72 Other human leukemia cell lines (for example, Reh), multiple myeloma cells and a prostatic carcinoma cell line demonstrated a similarly propensity to engraft at vascular domains in the BM. 72 Colmone et al. 60 subsequently demonstrated that the growth of Nalm-6 leukemic cells in vivo actively disrupted normal vascular niches for transplanted human CD34 þ cells and 're-directed' normal human CD34 þ cells to engraft in alternative niches within the BM. These studies suggest that human ALL cells may preferentially reside in association with microvascular domains and that ALL cells actively regulate the migration and engraftment of normal hematopoietic progenitors in the BM microenvironment. 60, 72 Progress has also been made in identifying specific mechanisms through which BM niches regulate LSC fate. For example, the CXC chemokine receptor type 4 (CXCR4)/stromal-cellderived factor 1 (SDF1) chemotaxis gradient is known to regulate normal HSC proliferation and survival. [73] [74] [75] [76] CXCR4 is also expressed on primary leukemic cells, and high expression of CXCR4 on AML cells is a negative prognostic factor of relapse-free and overall survival. [77] [78] [79] Inhibition of the CXCR4-SDF-1 interaction was shown to diminish the engraftment of the ALL cell line, Nalm-6, 72 in the BM vasculature following transplantation in mice. Nalm-6 ALL cells were able to downregulate SDF1 within the SDF1-rich microdomains to outcompete normal hematopoietic stem and progenitor cells. 80 Treatment with the CXCR4 antagonist, AMD3465, was shown to inhibit stromal cell-induced pro-survival signals in AML cells. 81 In addition, treatment with AMD3465 increased the sensitivity of Flt-3-mutated AML cells to the Flt-3 inhibitor, sorafenib and induced the mobilization of AML cells into the peripheral blood, yielding a reduction in AML burden in mice following sorafenib treatment. 81 Similarly, administration of another CXCR4 antagonist, AMD3100, increased the mobilization of murine APL cells and sequential treatment with AMD3100 and chemotherapy decreased tumor burden and increased survival of mice compared with treatment with chemotherapy alone. 82 These data suggest that LSCs possess CXCR4-dependent homing capacity that is analogous to normal hematopoietic cells, and antagonism of the CXCR4-SDF1 axis is a logical therapeutic strategy for the treatment of acute leukemia. Furthermore, the mechanisms that regulate LSC homing to BM niches may provide insights into tumor cell egress from the BM in the setting of tumor metastasis. 59 After homing to the BM vascular or osteoblastic niches, leukemic cells are retained in these niches through cellular adhesion molecules such as VLA-4 and LFA-1 integrins. 79 Increased VLA-4 expression has been shown to correlate with increased BM blast counts in AML. 83 Moreover, VLA-4 ( þ ) AML cells have relative resistance to drug-induced apoptosis, and administration of VLA-4 neutralizing antibodies eliminates this resistance. 84 These data suggest that interactions between VLA-4 on leukemic cells and fibronectin expressed on BM stromal cells may modulate chemotherapy sensitivity. 84 CD44, which is the receptor for hyaluronic acid, is also important for hematopoietic stem and progenitor cell homing to the vascular niche. 85 In both, a mouse model of chronic myelogenous leukemia and a xenograft model of human AML, treatment with an anti-CD44 antibody resulted in LSC mobilization from the niche, LSC differentiation and LSC eradication. 85, 86 Another strategy that has been tested to inhibit LSC homing to the BM is antagonism of the interleukin-3 receptor. Treatment of LSCs in ex vivo culture with anti-IL3 a chain neutralizing antibody, 7G3, significantly reduced engraftment of transplanted AML cells in NOD/SCID mice. 87 Transplantation of 87 The mechanism for the reduction in engraftment was due to blocking the homing capacity of AMLLSCs to the BM, and this resulted in prolonged survival of transplanted mice. 87 Perhaps because of a common origin, 30, 88 both hematopoietic progenitor cells and ECs share similar signaling pathways such as VEGFR-2 (KDR, human homologue). 89, 90 Leukemic cells have also been shown to also express VEGF and VEGFR-2.
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91,92
Dias et al. 92 demonstrated that VEGF has autocrine and paracrine functions that mediate leukemic cell proliferation and that systemic administration of anti-VEGFR-2 inhibited leukemic propogation in a NOD-SCID xenograft model. These studies suggest that targeted inhibition of VEGFR2 signaling is a viable strategy for anti-leukemogenesis. 92 Increased BM angiogenesis has also been described as a pathologic feature of acute leukemia, but the mechanisms through which acute leukemia cells mediate angiogenesis are not known. [93] [94] [95] ALL cells have been shown to secrete soluble factors that promote EC proliferation and migration in vitro. 96 In turn, BM ECs promote the survival of leukemia cells in vitro by modulation of the anti-apoptotic bcl-2 protein. 96 Similarly, culture of primary AML cells with lung or dermal ECs promotes EC proliferation in vitro. 97 Seandel et al. 98 showed that contact culture of HL60 cells with an E4ORF1 EC cell line also supports the expansion of HL60 cells in culture. These investigators also suggested that leukemic cell-induced upregulation of VEGFR2 signaling in E4ORF1 ECs led to the elaboration of angiocrine factors that promoted leukemic cell growth. 19, 98 Taken together, these studies suggest that leukemic cells elaborate growth factors, which augment EC proliferation, and ECs symbiotically mediate the proliferation and survival of leukemic cells. 19, 92, [96] [97] [98] In addition to the contribution of the BM vascular niche and other niche cells to leukemic cell growth, BM-derived ECs and stromal cells also regulate the establishment of metastatic niches for solid tumor cells. 59, 99, 100 Lyden et al. 101 showed that blockade of recruitment of BM ECs and BM HPCs to metastatic sites impairs tumor angiogenesis and cancer growth in vivo. Kaplan et al. 102 showed that VEGFR1 þ BM HPCs were responsible for establishing a pre-metastatic niche for tumor cells and that antibody-mediated inhibition of VEGFR1 signaling in vivo prevented tumor metastases in mice models. Recently, Raaijmakers et al. 103 showed that deletion of Dicer1 or the Schwachmann-Bodian-Diamond syndrome gene in BM mesenchymal cells induced the development of myelodysplasia and AML in mice in vivo. The latter results remarkably suggest that the transformation of BM niche cells may drive the development of certain hematologic malignancies. 103 
Ongoing questions and opportunities
The past decade has yielded remarkable progress in delineating the contribution of BM niche cells in the regulation of hematopoietic stem and progenitor cell homeostasis, mobilization and regeneration in vivo. In vitro and in vivo studies have also clearly demonstrated that ECs regulate the self-renewal and regeneration of adult HSCs (Table 1) . 16, 18, 19, [40] [41] [42] 45, 52, 53, 55, [104] [105] [106] Although mechanistic pathways such as Notch and CXCR4-SDF1 signaling have been shown to contribute to BM endosteal and reticular cell regulation of HSC fate in vivo, 4,7 the mechanisms through which BM ECs regulate HSC maintenance and regeneration remain less well defined. 3 In parallel, phenotypic and functional characterization of LSCs has been demonstrated, coupled with the demonstration of homing and engraftment of LSCs in vascular niches in vivo. 68, 72 The continued dissection of the mechanisms through which the vascular niche and other niches regulate normal HSC fate and regeneration in vivo will facilitate the development of therapies to accelerate hematopoietic reconstitution in vivo. Elucidation of the mechanistic cross-talk and co-regulation of normal and malignant hematopoiesis by osteoblasts, ECs, MSCs and other BM microenvironment cells will be a central objective of the coming decade. Table 1 Evidence of endothelial cell regulation of HSCs 
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